HAVCR2 and neoplasm: Notably, the combination therapy of anti-PD-1 mAb or anti-PD-L1 mAb plus anti-Tim-3 mAb plus/or anti-Lag-3 mAb showed remarkably additive effect in the cytotoxicity of the tumor antigen specific CTL clones against GC cells as compared to ICI monotherapy.